BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 12:00:00 PM | Browse: 1083 | Download: 902
Publication Name World Journal of Diabetes
Manuscript ID 6359
Country Sweden
Received
2013-10-15 10:18
Peer-Review Started
2013-10-16 10:12
To Make the First Decision
2013-11-12 14:29
Return for Revision
2013-11-13 14:58
Revised
2013-11-25 00:44
Second Decision
2013-12-13 13:31
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-12-13 14:17
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-12-17 18:39
Typeset the Manuscript
2014-02-15 16:54
Publish the Manuscript Online
2014-02-19 15:19
ISSN 1948-9358 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Review
Article Title Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Manuscript Source Invited Manuscript
All Author List Bo Ahrén
Funding Agency and Grant Number
Corresponding Author Dr. Bo Ahrén, Professor, Department of Clinical Sciences Lund, Lund University, B11 BMC, 221 84 Lund, Sweden. bo.ahren@med.lu.se
Key Words Type 2 diabetes; Glucose lowering; Insulin therapy; Glucagon-like peptide-1 receptor agonists; Dipeptidyl peptidase-4 inhibitors; Incretin therapy; Combination
Core Tip Incretin therapy (glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors) combined with insulin therapy is a glucose-lowering strategy in type 2 diabetes. The combination allows a complementary mode of mechanistic action and, as demonstrated in several clinical trials, is glucose-lowering in association with limited risk for hypoglycemia and weight gain. The combination is a promising strategy in patients in whom metformin with either incretin therapy or basal insulin is insufficient for adequate glycemic control. This article reviews the background and clinical studies on this combination.
Publish Date 2014-02-19 15:19
Citation Ahrén B. Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World J Diabetes 2014; 5(1): 40-51 Available from: URL: http://www.wjgnet.com/1948-9358/full/v5/i1/40.htm DOI: http://dx.doi.org/10.4239/wjd.v5.i1.40
URL http://www.wjgnet.com/1948-9358/full/v5/i1/40.htm
DOI http://dx.doi.org/10.4239/wjd.v5.i1.40
Full Article (PDF) WJD-5-40.pdf
Full Article (Word) WJD-5-40.doc
Manuscript File 6359-Review.docx
Answering Reviewers 6359-Answering reviewers.pdf
Copyright License Agreement 6359-Copyright assignment.pdf
Peer-review Report 6359-Peer review(s).pdf
Scientific Editor Work List 6359-Scientific editor work list.doc